PAGE analysis of BER activities of AlkA, hMPG and HeLa CFE1s for Oxa and Oxa–Sp

<p><b>Copyright information:</b></p><p>Taken from "Repair activity of base and nucleotide excision repair enzymes for guanine lesions induced by nitrosative stress"</p><p>Nucleic Acids Research 2005;33(7):2181-2191.</p><p>Published online 14 Apr 2005</p><p>PMCID:PMC1079971.</p><p>© The Author 2005. Published by Oxford University Press. All rights reserved</p> () 25OXA, 25OXA–SP and 34MG (all 2 nM, and ) were incubated with the indicated amounts of AlkA and hMPG at 37°C for 30 min. After incubation, the reaction mixture was treated with 0.1 M NaOH to cleave AP sites, and products were separated by 16% denaturing PAGE. The nicked products due to β-elimination (upper bands) and β,δ-elimination (lower bands) are indicated by open brackets. () 25OXA and 25HX (both 2 nM, and ) were incubated in hMPG buffer with the indicated amounts of HeLa CFE1s at 37°C for 1 h. Products were analyzed as described above

Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer - Fig 2

<p>Kaplan–Meier overall survival curves after the diagnosis of NSCLC in all patients with or without pneumonitis during systemic anti-cancer therapy (pneumonitis) (Fig 2A) and those who did not have pre-existing ILD with or without pneumonitis (Fig 2B), and survival time after the onset of pneumonitis in survivors of pneumonitis (Fig 2C).</p

Analyses of survival time after pneumonitis during systemic anti-cancer therapy (N = 28^*)

<p>Analyses of survival time after pneumonitis during systemic anti-cancer therapy (N = 28^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0168465#t005fn002" target="_blank">*</a>})</p

Analyses of overall survival time in all patients (N = 770)

<p>Analyses of overall survival time in all patients (N = 770)</p

Characteristics and outcomes of patients with pneumonitis during systemic anti-cancer therapy (N = 44)

<p>Characteristics and outcomes of patients with pneumonitis during systemic anti-cancer therapy (N = 44)</p

Characteristics of and comparison between patients with and without pneumonitis during systemic anti-cancer therapy

<p>Characteristics of and comparison between patients with and without pneumonitis during systemic anti-cancer therapy</p

Factors associated with pneumonitis during systemic anti-cancer therapy (N = 770)

<p>Factors associated with pneumonitis during systemic anti-cancer therapy (N = 770)</p

Additional file 2: Figure S1. of The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma

Scatter-plot of serum CA 19-9 and CYFRA 21-1 levels. (JPG 394 kb